Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment.

Stijn W van BeekLénaïg TanneauGraeme MeintjesSean WassermanNeel R GandhiAngie CampbellCharle A ViljoenLubbe WiesnerRob E AarnoutseGary MaartensJames C M BrustElin M Svensson

Published in: Open forum infectious diseases (2022)

Our simulations enable an informed decision for a suitable ECG monitoring strategy by weighing the risk of missing patients with QTcF > 500 ms and that of interrupting bedaquiline treatment unnecessarily. We propose ECG monitoring before treatment and at weeks 2, 4, 8, and 12 after starting bedaquiline treatment.

Keyphrases

multidrug resistant
multiple sclerosis
heart rate variability
ms ms
molecular dynamics